R/R Cll

How to approach R/R CLL

VJHemOnc – Video Journal of Hematology & HemOnc

Primary analysis of TRANSCEND-CLL-004: liso-cel in R/R CLL

VJHemOnc – Video Journal of Hematology & HemOnc

The role of MRD in clinical decision-making in R/R CLL

VJHemOnc – Video Journal of Hematology & HemOnc

Sequence of administration of ibrutinib with obinutuzumab in R/R CLL patients

VJHemOnc – Video Journal of Hematology & HemOnc

Epcoritamab monotherapy and combinations in R/R CLL and Richter’s syndrome

VJHemOnc – Video Journal of Hematology & HemOnc

Additional Therapies for R/R CLL

Therapeutic Approaches for R/R CLL

Acalabrutinib vs ibrutinib in R/R CLL: assessing the burden of adverse events

VJHemOnc – Video Journal of Hematology & HemOnc

CLL-Frail trial: efficacy & safety of acalabrutinib in elderly (≥80y) and/or frail patients with CLL

VJHemOnc – Video Journal of Hematology & HemOnc

Zanubrutinib improves PFS compared to ibrutinib for R/R CLL and small lymphocytic lymphoma

R/R CLL: combination therapy and tailored treatment

VJHemOnc – Video Journal of Hematology & HemOnc

Venetoclax + rituximab for R/R CLL: 7-year results of the MURANO trial

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Davids on Rationale for Ibrutinib/Umbralisib Combo in R/R CLL and MCL

Venetoclax and ibrutinib for R/R CLL: analysis from the VIsion/HO141 trial

VJHemOnc – Video Journal of Hematology & HemOnc

MURANO: venetoclax + rituximab in BIRC3-mutated R/R CLL

VJHemOnc – Video Journal of Hematology & HemOnc

BTK Inhibitors in R/R CLL

ASCEND: acalabrutinib in R/R CLL

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Jones on Studying Venetoclax in R/R CLL

Venetoclax and rituximab: changing the treatment landscape in R/R CLL

VJHemOnc – Video Journal of Hematology & HemOnc

The VENICE-1 trial: venetoclax monotherapy in R/R CLL

VJHemOnc – Video Journal of Hematology & HemOnc